anti ulbp1 primary antibody (R&D Systems)
Structured Review

Anti Ulbp1 Primary Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ulbp1/Human+ULBP-1+Antibody/pmc12929413-77-23-29
Average 94 stars, based on 25 article reviews
Images
1) Product Images from "Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma"
Article Title: Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma
Journal: Frontiers in Immunology
doi: 10.3389/fimmu.2026.1739503
Figure Legend Snippet: Transcriptomic profiling reveals upregulation of ULBP1 and ferroptosis-related genes following Erastin treatment. (A) Volcano plots showing differentially expressed genes in KELLY and SK-N-AS neuroblastoma cell lines treated with 1 µM and 2 µM Erastin for 24 hours, respectively, compared to DMSO control. Non-significant genes are shown in gray; significantly upregulated and downregulated genes are shown in red and blue, respectively. (B) KEGG pathway enrichment analysis of DEGs in KELLY and SK-N-AS cells, showing significantly enriched pathways including ferroptosis and amino acid metabolism. (C) Gene Ontology (GO) enrichment network highlighting clusters associated with oxidative stress response, amino acid metabolic processes, and signaling receptor binding, with key genes indicated.
Techniques Used: Control, Binding Assay
Figure Legend Snippet: Low ULBP1 expression correlates with poor prognosis in neuroblastoma patients from the SEQC cohort. Kaplan–Meier overall survival analysis was performed using the SEQC neuroblastoma dataset (n = 498) via the R2 Genomics Analysis and Visualization Platform (A) Complete cohort; (B) MYCN -amplified subset; (C) Patients with progressive disease; (D) INSS stage 4 subset.
Techniques Used: Expressing, Amplification
Figure Legend Snippet: Erastin treatment increases ULBP1 surface expression and enhances NK cell-mediated cytotoxicity in neuroblastoma cells. (A) Surface expression of ULBP1 was measured by flow cytometry in KELLY, SK-N-AS, SK-N-BE (2), and SK-N-FI cells treated with DMSO (control) or Erastin. (B) NK cell-mediated cytotoxicity assay using NK-92 cells co-cultured with neuroblastoma cells (E:T ratio was 8:1) pre-treated with either DMSO (Control), Erastin, or Erastin in combination with Liproxstatin-1 (Lip-1). Cell lysis percentages were quantified in KELLY, SK-N-AS, and SK-N-FI cells. n = 3 biologically independent experiments. *P<0.05, **P<0.01, ***P<0.001; Paired t test.
Techniques Used: Expressing, Flow Cytometry, Control, Cytotoxicity Assay, Cell Culture, Lysis
Related Articles
Recombinant:Article Title: Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL Article Snippet: Flow cytometry experiments were performed using antibodies directed against human CD4 (560158, BD Biosciences), CD8 (561453, BD Biosciences), CD19 (562441, BD Biosciences), CD25 (53-0259-42, ThermoFisher), CD34 (343516, Biolegend), CD45RA (564552, BD Biosciences), CD62L (25-0629-42, ThermoFisher), CD69 (555533, BD Biosciences), CD107a (328620, Biolegend), CD279 (12-2799-42, ThermoFisher), TIGIT (372714, Biolegend) and TCRα/β (130-113-527, Miltenyi). .. NKG2DL were detected using antibodies directed against human MICA (FAB1300P, R&D systems), MICB (FAB1599P, R&D systems), Article Title: MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated Article Snippet: After incubation for 16 h at 4°C under humidity, plates were washed with PBS-containing 0.05% Tween-20 (PBS-T) and blocked with 1% casein-PBS at pH = 7.4 (Biorad, Hercules, California, United States) for 2 h at 37°C. .. Standard dilutions were prepared from recombinant human MICA (1300-MA), MICB (1599-MB-050), Labeling:Article Title: Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma Article Snippet: .. After pretreatment, cells were washed with PBS and labeled with either Article Title: Reducing fratricide of immune cells expressing NKG2D-based receptors Article Snippet: These results indicate that target-driven fratricide can be overcome using different approaches that can enable the development of T cell therapies where self-expression of the target ligand is a limiting factor. .. Materials and Methods Antibodies and Flow Cytometry Cells were stained with fluorochrome labeled CD3 (BD, 345766), CD4 (BD, 345809), CD8 (BD, 345772), CD314 (BD, 558071), CD45RA (BD, 550855), CD62L (BD, 555544), CD279 (eBioscience, 12-2799-42), CD19 (BD, 345791, CD223 (eBioscience, 25-2239-41), MICA/B (R&D Systems, FAB13001G-100), MICB (R&D Systems, FAB1599G), Article Title: Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Article Snippet: .. After pretreatment, cells were washed with PBS and labeled with either Flow Cytometry:Article Title: Reducing fratricide of immune cells expressing NKG2D-based receptors Article Snippet: These results indicate that target-driven fratricide can be overcome using different approaches that can enable the development of T cell therapies where self-expression of the target ligand is a limiting factor. .. Materials and Methods Antibodies and Flow Cytometry Cells were stained with fluorochrome labeled CD3 (BD, 345766), CD4 (BD, 345809), CD8 (BD, 345772), CD314 (BD, 558071), CD45RA (BD, 550855), CD62L (BD, 555544), CD279 (eBioscience, 12-2799-42), CD19 (BD, 345791, CD223 (eBioscience, 25-2239-41), MICA/B (R&D Systems, FAB13001G-100), MICB (R&D Systems, FAB1599G), Staining:Article Title: Reducing fratricide of immune cells expressing NKG2D-based receptors Article Snippet: These results indicate that target-driven fratricide can be overcome using different approaches that can enable the development of T cell therapies where self-expression of the target ligand is a limiting factor. .. Materials and Methods Antibodies and Flow Cytometry Cells were stained with fluorochrome labeled CD3 (BD, 345766), CD4 (BD, 345809), CD8 (BD, 345772), CD314 (BD, 558071), CD45RA (BD, 550855), CD62L (BD, 555544), CD279 (eBioscience, 12-2799-42), CD19 (BD, 345791, CD223 (eBioscience, 25-2239-41), MICA/B (R&D Systems, FAB13001G-100), MICB (R&D Systems, FAB1599G), |
